Key result
Insulin resistance linked to ~49-fold higher 30-day major cardiovascular events risk in non-diabetic PCI patients.
Why the study?
There was no data regarding the clinical effect of insulin resistance on outcomes of PCI in non-diabetic patients.
Does insulin resistance (HOMA-IR >= 2.6) increase the risk of MACE in non-diabetic patients undergoing elective coronary angiography and PCI?
Cohort (n=98)
No
Does insulin resistance (HOMA-IR >= 2.6) increase the risk of MACE in non-diabetic patients undergoing elective coronary angiography and PCI?
Increased insulin resistance (HOMA-IR >= 2.6) is an independent predictor of short-term MACE in non-diabetic patients undergoing elective coronary angiography and PCI.
Answers are grounded in this paper and cite their sources.
HOMA-IR may aid post-PCI risk stratification in non-diabetics; leaves open whether targeting insulin resistance improves outcomes.
Insulin resistance is an important risk factor for coronary artery disease. However, there has been no data regarding its clinical effect on the outcomes of percutaneous coronary intervention (PCI) in non-diabetic patients. We analyzed 98 non-diabetic consecutive patients (59+/-11.5 yr, male:female=63:35) who underwent elective coronary angiography. The patients were divided into two groups: Group I (n=71; the value of HOMA-IR [homeostasis model assessment of insulin resistance] <2.6) and Group II (n=27; the value of HOMA-IR > or = 2.6). In-hospital and 30-day major adverse cardiac events (MACE) were compared between the two groups. The concentrations of fasting insulin and triglyceride were significantly higher in Group II than in Group I. Significant correlations were observed between the value of HOMA-IR and body mass index (r=0.489, p<0.001), levels of total cholesterol (r=0.204, p=0.045), triglyceride (r=0.334, p=0.001) and apolipoprotein B (r=0.212, p=0.038). PCI was performed in 59 patients (60.2%). In-hospital and 30-day MACE were higher in Group II than Group I (2.4% vs. 27.8%, p=0.008; 2.4% vs. 27.8%, p=0.008). Multivariate analysis revealed that the value of HOMA-IR > or = 2.6 was an independent predictor of MACE. Increased HOMA-IR level is an important prognostic indicator in non-diabetic patients underwent PCI.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2006) conducted a cohort in Coronary Artery Disease (n=98). Insulin resistance (HOMA-IR ≥ 2.6) vs. HOMA-IR < 2.6 was evaluated on 30-day major adverse cardiac events (MACE) (OR 49.27, 95% CI 1.05-231.13, p=0.048). In non-diabetic patients undergoing percutaneous coronary intervention, insulin resistance was an independent predictor of 30-day major adverse cardiac events.
Synapse has enriched 10 related papers. Consider them for comparative context: